Lilly begins phase III trial for COVID-19 therapy



19 June, 2020   News

This article was originally published by The Science Advisory Board staff writers on the digital media The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes.

Eli Lilly has enrolled patients in a phase III study to evaluate the efficacy and safety of baricitinib in hospitalized adults with COVID-19.

Baricitinib, marketed by the company as Olumiant, is an oral Janus kinase (JAK)1/JAK2 inhibitor licensed from Incyte that has been approved in 70 countries as a treatment for rheumatoid arthritis.

COVID-19 can be associated with a hyperinflammatory state and JAK1/JAK2 inhibition may reduce the cytokine storm caused by SARS-CoV-2 infection. In addition to being a JAK1/JAK2 inhibitor, baricitinib may also inhibit cell host proteins that assist in viral reproduction, thereby reducing the ability of infected cells to produce more virus.

Lilly expects to enroll 400 patients in the randomized, double-blind, placebo-controlled study. The study will be conducted in the U.S., Europe, and Latin America and will include patients hospitalized with SARS-CoV-2 infection who have at least one elevated marker of inflammation but who do not require invasive mechanical ventilation. Patients will be dosed with 4 milligrams of baricitinib daily or placebo for up to 14 days or until discharge.

Upon successful approval for use of baricitinib in COVID-19, Lilly will continue to create adequate supply to support both appropriate clinical and investigational use.

This study will complement data from a study of baricitinib with remdesivir in the second phase of the Adaptive COVID-19 Treatment Trial (ACTT-2) run by the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health.

Keep up to date on Innoget's initiative to beat Covid-19 by following the dedicated channel where new innovation needs, novel technologies, news, and events are posted daily.

Other News

SHV Energy Launches New Open Innovation Portal

  • 23 April, 2021

Innovation and an ecosystem of partners are crucial in our mission to Advance Energy Together, providing cleaner energy for all. SHV Energy launches an open innovation portal to find new partners to co-develop innovative solutions, find new ideas and create mutual opportunities. As a global energy group we recognise, and embrace the challenge to continue to provide essential energy solutions to off-grid customers that are envir...

Read more about this

  • 21 April, 2021

In the framework of this collaboration, we have issued a new challenge to the innovation ecosystem, focused on the digitalization of the circular economy flow. Currently, there is a growing demand in the market for packaging containers or products elaborated from recycled materials. Thus, we need to identify solutions that help us certify that the raw materials we produce from waste at the Valoriza Servicios Medioambientales (VSM) plants are i...

Read more about this

  • 16 February, 2021

EINST4INE - The European Training Network for Industry Digital Transformation project will explore various aspects of #digitaltransformation spread across interconnected research areas such as: ...

Read more about this

Find More News